Idéal Investisseur
Français English
CAC 40 : Market open
8 481,01 pts
-0.04%


Last updated : 24/08/2026 - 11h47
🏠 Home   ➤    Stock news

TME Pharma: Advanced Negotiations for NOX-A12 Licensing Agreement

The biotechnology company provided an update on its activities on August 24, 2026, clarifying that it is entering the final evaluation phase of advanced negotiations with two potential partners for a licensing agreement covering its main oncology asset.

The group is now approaching the partner selection phase to ensure advanced-stage development and commercialization of NOX-A12.


TME Pharma: Advanced Negotiations for NOX-A12 Licensing Agreement

Licensing Agreement to Continue NOX-A12 Development

NOX-E36 Redirected Toward Licensing, GRDC Project Abandoned

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
Before 9 AM every morning Euronext data AI-powered analysis
Related


Sector Industrie Pharmaceutique et Biotechnologie Biotechnologie


Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext

Context

Period
  • Period: 2025
Key reported figures
  • Net income: -3,3M€
Guidance from the release
  • En tant qu'actionnaire et administrateur, je reste optimiste quant à l'avenir de TME Pharma.
Risks mentioned
  • Les capitaux propres au 31 décembre 2025 sont désormais négatifs de 1,6 million d'euros.
  • L'absence de chiffre d'affaires génère des incertitudes financières.
Opportunities identified
  • TME Pharma se concentre sur la conclusion d'accords de licence pour NOX-A12 et NOX-E36.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
Avant 9h00 1000+ inscrits 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours